Rezultati pretraživanja
  1. prije 35 minuta

    I'm a healthy adult and I don't have to worry about at all ! 🤷 If this is what you think, you must definitely read these myths and facts about

  2. 2️⃣ in kids, Plasma N-terminal propeptide of type III collagen AUROC F3 0.993 3️⃣ blocking platelet activation via ASA, ADP-P2Y12 R inhibitor or ant-GP1balpha antibodies may ⬇️ HCC (ASA, ADP), NASH (GP1) and fibrosis progress (ASA)

    Prikaži ovu nit
  3. prije 3 sata

    This is an exciting advancement. Will be adding to my toolbox.

  4. prije 3 sata
    Odgovor korisniku/ci

    thank you for increasing awareness on the dangers of . NASH is soon to become the leading cause of liver transplants and is already the second most common liver disease on the liver transplant list.

  5. prije 4 sata

    Fascinating paper shares insights into advances made in the field of nonalcoholic fatty liver disease () in 2019.

  6. prije 11 sati
    Odgovor korisnicima

    Congratulations on this important contribution , Stephen Harrison and many others! Now I can stop hitting refresh waiting for the full paper. Fantastic resource for pts with

  7. prije 11 sati

    Does one need to get a liver biopsy to asses non-alcoholic fatty liver disease status?

  8. prije 12 sati

    will start with the PGC "Lifestyle and the liver". 1st session is on . Chaired by Jean-François Dufour and Helen Louise Reeves. Lectures from them and Elisabetta Bugianesi, Guruprasad Aithal, . Register here:

  9. prije 13 sati

    is a major predisposing factor to hepatic insulin resistance, NASH, & T2D. New therapies are required to reverse NAFLD, insulin resistance, & diabetes. Learn more about the CRMP treatment method the Shulman Lab () developed during this webinar.

  10. prije 14 sati

    The incidence of is rising and it's estimated 1 in 3 adults in the U.K. are in the early stages of NAFLD.

  11. Gut in hepatocellular carcinoma pathogenesis, noninvasive detection of liver fibrosis & the role of platelets in the development of NASH in this What were your top picks of research in 2019?

  12. Is screening for in primary care worth the cost?

  13. 4. velj

    . Clinical Practice Update on Screening and Surveillance for in Patients with : Expert Review

  14. New article coming soon from our research group on risk of including possibility for to improve this

  15. 4. velj

    Here's our recent paper on screening in patients with published in

  16. Why is good for my ? Let's start with five reasons... more to follow 1️⃣Improves blood flow 2️⃣Lowers HVPG 3️⃣Improves 4️⃣Protects against damage 5️⃣Decrease in risk, including

  17. 4. velj

    Happy to contribute to this meta-analysis on the prognostic value of fibrosis and on hard outcomes in : Take home: remains key to risk prediction, also in pts w/o NASH.

  18. 3. velj

    Today we proudly celebrate 3 years of the Petsalaki group! Working on ! Exciting stories coming this year from the lab so watch this space and let us know what you think :)

  19. Should People With Disease Be Monitored for Liver ? 👉 "People with or its more severe form, , who have developed should be monitored regularly for ."

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.